|
|
|
|
|
|
|
|
|
|
ImmunoGen Says IND For Anticancer Compound IMGN853 Is Now Active
(RTTNews.com) - ImmunoGen, Inc. (IMGN) announced that the Investigational New Drug, or IND, application for its IMGN853 product candidate is now active. IMGN853 is a potential new therapeutic for ovarian cancer, non-small cell lung cancer and other epithelial malignancies which over-express folate receptor 1, or FOLR1.
The company expects Phase I evaluation of IMGN853 to commence in the middle of 2012.....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.